SMNRW 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-10

• On March 18, 2019, Legacy Semnur was acquired by Scilex pursuant to an Agreement and Plan of Merger with Semnur (as amended, the “Legacy Semnur Merger Agreement”), Sigma Merger Sub, Inc., a wholly owned subsidiary of Scilex (“Sigma Merger Sub”), Fortis Advisors LLC, solely as representative of the h…

• achievement of $250.0 million in cumulative net sales of our product, (iii) a $50.0 million payment upon the achievement of $500.0 million in cumulative net sales of our product, and (iv) a $150.0 million payment upon the achievement of $750.0 million in cumulative net sales of our product. To date,…

• We expect that our general and administrative expenses will vary year over year in the future as we adapt our strategies to changes in the business environment. We also expect to incur increased expenses as a result of operating as a public company, including expenses related to compliance with the …

• Comparison of the three and six months ended June 30, 2026 and 2025

• Total research and development expenses for the three months ended June 30, 2026 and 2025 were $1.2 million and $0.5 million, respectively. The increase of $0.7 million was primarily driven by higher contracted research and development expenses of approximately $0.4 million, principally consisting o…

相对上期删除的文字 · 来源:10-Q · 2026-05-13

• On March 18, 2019, Legacy Semnur was acquired by Scilex pursuant to an Agreement and Plan of Merger with Semnur (as amended, the “Legacy Semnur Merger Agreement”),

• fees for legal, patent, accounting, auditing, tax and consulting services and expenses related to the Business Combination.

• We expect that our general and administrative expenses will vary year over year in the future as we adapt our strategies to changes in the business environment. We also expect to incur increased expenses as a result of operating as a public company, including expenses related to compliance with the …

• Comparison of the Three Months Ended March 31, 2026 and 2025

• Total research and development expenses for the three months ended March 31, 2026 and 2025 were $1.3 million and $0.2 million, respectively. The increase of $1.1 million was primarily driven by higher personnel‑related costs of approximately $0.3 million due to increased full‑time equivalent headcou…

相对上期新增的文字 · 来源:10-Q · 2026-08-10

• We are a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative

• non-opioid pain management products for the treatment of acute and chronic pain, and we have a limited operating history. We have not commenced revenue-producing operations and to date, we have focused on organizing and staffing our company, business planning, raising capital, identifying potential …

• At present, we have no sales or marketing personnel. We intend to leverage the sales force and marketing capacities of our parent company, Scilex, to commercialize our current product candidate, SP-102, if approved. As we further grow after the launch of SP-102, if approved, we will establish our sa…

• Even if we enter into third-party marketing and distribution arrangements, we may have limited or no control over the sales, marketing and distribution activities of these third parties. Our future revenues may depend heavily on the

• Our ability to become a profitable operating company is dependent upon our ability to generate revenue and obtain financing adequate to fulfill our development and commercialization activities, and achieving a level of revenue adequate to support our cost structure. We have plans to obtain additiona…

相对上期删除的文字 · 来源:10-Q · 2026-05-13

• The Company intends to use the net proceeds of the Biconomy SPA, which as of the date of this Quarterly Report on Form 10-Q has not closed and will be paid in Bitcoin, to fund investments in other companies. The price of Bitcoin will likely continue to be highly volatile, which could cause the Compa…

• Our cryptocurrency treasury strategy has not been implemented or tested.

• If any of the digital assets that we hold are classified as a security, we may be subject to extensive regulation, which could result in significant costs or force us to cease operations.

• We are a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative non-opioid pain management products for the treatment of acute and chronic pain, and we have a limited operating history. We have not commenced revenue-producing operations and to date, we hav…

• At present, we have no sales or marketing personnel. We intend to leverage the sales force and marketing capacities of our parent company, Scilex, to commercialize our current product candidate, SP-102, if approved. As we further grow after the launch of the SP-102, if approved, we will establish ou…